These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. Maher AR; Theodore G J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Sheehan JJ; Reilly KR; Fu DJ; Alphs L Innov Clin Neurosci; 2012 Jul; 9(7-8):17-23. PubMed ID: 22984648 [TBL] [Abstract][Full Text] [Related]
4. Olanzapine versus other atypical antipsychotics for schizophrenia. Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348 [TBL] [Abstract][Full Text] [Related]
5. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020. Yıldız M; Osman E Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516 [TBL] [Abstract][Full Text] [Related]
6. Risperidone versus other atypical antipsychotics for schizophrenia. Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678 [TBL] [Abstract][Full Text] [Related]
7. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
9. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study. Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Jones MP; Nicholl D; Trakas K Int J Clin Pharmacol Ther; 2010 Jun; 48(6):383-99. PubMed ID: 20497747 [TBL] [Abstract][Full Text] [Related]
11. Clozapine versus other atypical antipsychotics for schizophrenia. Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole. Remmerie B; De Meulder M; Ariyawansa J; Savitz A Clin Pharmacol Drug Dev; 2016 Nov; 5(6):538-547. PubMed ID: 27363344 [TBL] [Abstract][Full Text] [Related]
13. [Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics]. Kyziridis TC Psychiatriki; 2022 Jun; 33(2):139-148. PubMed ID: 34390562 [TBL] [Abstract][Full Text] [Related]
14. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Owen RT Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Melnik T; Soares BG; Puga ME; Atallah AN Sao Paulo Med J; 2010 May; 128(3):141-66. PubMed ID: 20963366 [TBL] [Abstract][Full Text] [Related]
16. Aripiprazole versus other atypical antipsychotics for schizophrenia. Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570 [TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Mauri MC; Volonteri LS; Colasanti A; Fiorentini A; De Gaspari IF; Bareggi SR Clin Pharmacokinet; 2007; 46(5):359-88. PubMed ID: 17465637 [TBL] [Abstract][Full Text] [Related]